BIO-key International Reports Q1'25 Revenue Increase of 10% Sequentially, Net Loss Widens to $736K, EPS at ($0.16)

Reuters
2025/05/16
BIO-key International Reports Q1'25 Revenue Increase of 10% Sequentially, Net Loss Widens to $736K, EPS at ($0.16)

BIO-key International Inc., a provider of Identity and Access Management solutions, reported its financial results for the first quarter of 2025. The company recorded a revenue of $1.6 million, marking an approximate 10% sequential increase compared to the fourth quarter of 2024. However, year-over-year revenue saw a decline of 25%, primarily due to a significant two-year contract with a financial services customer in Q1'24 worth $1.2 million, compared to $690,000 recorded in Q1'25 for incremental biometric capabilities. The company's gross profit decreased to $1.33 million in Q1'25 from $1.88 million in Q1'24, with gross margins of 82.6% and 86.3%, respectively. The decline in gross profit was attributed to lower revenue and increased lower margin hardware sales. Operating expenses were reduced by $422,195 to $1.97 million in Q1'25 from $2.39 million in Q1'24, mainly due to a 23% reduction in selling, general, and administrative expenses. This decrease was a result of lower administration, sales personnel costs, and professional service fees. BIO-key's net loss increased to $736,545 in Q1'25, compared to a net loss of $510,285 in Q1'24. The company's cash position improved significantly to $3.1 million, reflecting proceeds from warrant exercises early in Q1'25, contributing to a total current asset value of $4.6 million as of March 31, 2025. Looking ahead, BIO-key anticipates significant revenue increase from its long-term financial services customer in 2026, driven by expanded deployments and the addition of a new biometric ID system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BIO-key International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-017237), on May 15, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10